819 Extragenital lichen sclerosus is an immune-related adverse event with nivolumab

Nivolumab is a programmed cell death (PD)-1 ligand inhibitor used in treatment of melanoma and other malignancies. Immune-related adverse events (IRAEs) affect nearly all organ systems, most commonly the skin, the gastrointestinal tract (enterocolitis), the liver (hepatitis), and the endocrine system. Skin reactions related to immunotherapy occur in 4-27% of patients, including lichenoid mucocutaneous eruptions, vitiligo, psoriasis, lichen planus, and bullous pemphigoid. Most recently, genital lichen sclerosus (LS) and relapse of morphea have been reported.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Pigmentation and Melanoma Source Type: research